BidaskClub downgraded shares of Inovio Pharmaceuticals, Inc. (NASDAQ:INO) from a hold rating to a sell rating in a research report released on Friday.

INO has been the topic of several other reports. Zacks Investment Research upgraded shares of Inovio Pharmaceuticals from a sell rating to a hold rating in a research report on Monday, May 15th. Stifel Nicolaus reiterated a buy rating and set a $11.00 target price on shares of Inovio Pharmaceuticals in a research report on Tuesday, April 25th. BNP Paribas reiterated a neutral rating and set a $39.00 target price on shares of Inovio Pharmaceuticals in a research report on Monday, May 1st. HC Wainwright set a $13.00 target price on shares of Inovio Pharmaceuticals and gave the stock a buy rating in a research report on Friday, July 7th. Finally, Aegis lifted their target price on shares of Inovio Pharmaceuticals from $11.00 to $14.00 and gave the stock a buy rating in a research report on Thursday, May 25th. Two analysts have rated the stock with a sell rating, two have issued a hold rating and nine have issued a buy rating to the stock. The stock currently has an average rating of Buy and an average price target of $19.90.

Shares of Inovio Pharmaceuticals (NASDAQ:INO) traded down 2.608% during trading on Friday, reaching $5.415. 859,410 shares of the company traded hands. Inovio Pharmaceuticals has a 12-month low of $5.39 and a 12-month high of $11.00. The firm’s market capitalization is $404.11 million. The company has a 50 day moving average price of $7.45 and a 200 day moving average price of $6.88.

Inovio Pharmaceuticals (NASDAQ:INO) last posted its earnings results on Wednesday, May 10th. The biopharmaceutical company reported ($0.31) EPS for the quarter, hitting the consensus estimate of ($0.31). Inovio Pharmaceuticals had a negative net margin of 235.91% and a negative return on equity of 65.97%. The business had revenue of $10.40 million for the quarter, compared to the consensus estimate of $5.83 million. During the same period last year, the company earned ($0.11) EPS. The firm’s revenue was up 28.4% compared to the same quarter last year. On average, equities analysts predict that Inovio Pharmaceuticals will post ($1.09) EPS for the current year.

ILLEGAL ACTIVITY NOTICE: “Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Downgraded to “Sell” at BidaskClub” was originally posted by Watch List News and is the property of of Watch List News. If you are reading this story on another website, it was illegally stolen and republished in violation of US and international copyright laws. The legal version of this story can be accessed at https://www.watchlistnews.com/inovio-pharmaceuticals-inc-nasdaqino-downgraded-to-sell-at-bidaskclub/1465710.html.

In other news, Director David B. Weiner sold 8,000 shares of Inovio Pharmaceuticals stock in a transaction on Thursday, May 25th. The shares were sold at an average price of $8.00, for a total value of $64,000.00. Following the completion of the sale, the director now owns 740,956 shares in the company, valued at approximately $5,927,648. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 10.60% of the company’s stock.

A number of hedge funds have recently made changes to their positions in the stock. Russell Investments Group Ltd. acquired a new stake in shares of Inovio Pharmaceuticals during the fourth quarter worth approximately $559,000. Wells Fargo & Company MN raised its stake in Inovio Pharmaceuticals by 28.9% in the first quarter. Wells Fargo & Company MN now owns 124,565 shares of the biopharmaceutical company’s stock valued at $825,000 after buying an additional 27,898 shares during the last quarter. Stoneridge Investment Partners LLC raised its stake in Inovio Pharmaceuticals by 0.8% in the first quarter. Stoneridge Investment Partners LLC now owns 254,449 shares of the biopharmaceutical company’s stock valued at $1,684,000 after buying an additional 2,073 shares during the last quarter. Bank of New York Mellon Corp raised its stake in Inovio Pharmaceuticals by 3.6% in the first quarter. Bank of New York Mellon Corp now owns 342,348 shares of the biopharmaceutical company’s stock valued at $2,266,000 after buying an additional 11,765 shares during the last quarter. Finally, American International Group Inc. raised its stake in Inovio Pharmaceuticals by 7.1% in the first quarter. American International Group Inc. now owns 40,856 shares of the biopharmaceutical company’s stock valued at $270,000 after buying an additional 2,695 shares during the last quarter. Institutional investors and hedge funds own 22.90% of the company’s stock.

About Inovio Pharmaceuticals

Inovio Pharmaceuticals, Inc (Inovio) is a clinical-stage pharmaceutical company, which is involved in developing deoxyribonucleic acid (DNA) immunotherapies and vaccines focused on treating and preventing cancers and infectious diseases. The Company’s DNA-based immunotherapies, in combination with its electroporation delivery devices, generates immune responses, in particular T cells, in the body to fight target diseases.

Analyst Recommendations for Inovio Pharmaceuticals (NASDAQ:INO)

Receive News & Ratings for Inovio Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inovio Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.